BLA 761388 · Genentech INC
Piasky
Crovalimab-Akkz · Intravenous · Complement C5 Inhibitor
NovelOrphanCDER novel approval, Jun 20, 2024: To treat paroxysmal nocturnal hemoglobinuria
Last checked: Nov 20, 2026Latest source record: May 14, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2024
Jun 20, 2024
Approved uses
1
Original approval plus efficacy supplements
Registered trials
10
6 Phase 3, 0 recruiting
FAERS reports
121
115 serious, 12 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: SERIOUS MENINGOCOCCAL INFECTIONS PIASKY, a complement inhibitor, increases the risk of serious infections caused by Neisseria meningitidis [see Warnings and Precautions (5.1) ] . Life-threatening and fatal meningococcal infections have occurred in patients treated with complement inhibitors. These infections may become rapidly life-threatening or fatal if not recognized and treated early. Complete or update vaccination for meningococcal bacteria (for serogroups A, C, W, Y, and B) at least 2 weeks prior to the first dose of PIASKY, unless the risks of delaying therapy with PIASKY outweigh the risk of developing a serious infection. Comply with the most current Advisory Committee on Immunization Practices (ACIP) recommendations for meningococcal vaccination in patients receiving a complement inhibitor. See Warnings and Precautions (5.1) for additional guidance on the management...
What it is approved for
From the label in effect Nov 11, 2025.
PIASKY is indicated for the treatment of adult and pediatric patients 13 years and older with paroxysmal nocturnal hemoglobinuria (PNH) and body weight of at least 40 kg. PIASKY is a complement C5 inhibitor indicated for the treatment of adult and pediatric patients 13 years and older with paroxysmal nocturnal hemoglobinuria (PNH) and body weight of at least 40 kg ( 1 )
Mechanism: Crovalimab-akkz is a monoclonal antibody that specifically binds with high affinity to the complement protein C5, inhibiting its cleavage into C5a and C5b, preventing the formation of the membrane attack complex (MAC). Crovalimab-akkz inhibits terminal complement-mediated intravascular hemolysis in patients with PNH.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jun 20, 2024 Original approval · Type 1 - New Molecular Entity NovelOrphanLetterLabelMedication Guide
1 products under this application
- PIASKY · CROVALIMAB-AKKZ 340MG/2ML(170MG/ML) · INJECTABLE, INTRAVENOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Crovalimab" as an intervention, any sponsor and status, largest first.
- A Study Evaluating the Efficacy and Safety of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated With Complement InhibitorsPivotal-lookingActive, not recruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT04434092 · 210 participants · Start Oct 8, 2020 · Primary completion Nov 16, 2022
Drug: Crovalimab; Eculizumab · For: Paroxysmal Nocturnal Hemoglobinuria
Sites: Ciudad Autonoma Buenos Aires, Argentina; Santo André, Brazil; São Paulo, Brazil · 63 sites in all
- A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Complement InhibitorsPivotal-lookingActive, not recruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT04432584 · 190 participants (planned) · Start Sep 30, 2020 · Primary completion Apr 18, 2027
Drug: Crovalimab; Eculizumab · For: Paroxysmal Nocturnal Hemoglobinuria
Sites: Charlotte, North Carolina; Columbus, Ohio; Brussels, Belgium · 80 sites in all
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT05075824 · 95 participants · Start Mar 9, 2022 · Primary completion Jun 11, 2025
Drug: Crovalimab; Placebo · For: Sickle Cell Disease
Sites: Detroit, Michigan; Madison, Mississippi; New York, New York · 27 sites in all
- A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS)Pivotal-lookingActive, not recruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT04861259 · 83 participants · Start Oct 22, 2021 · Primary completion Oct 9, 2025
Drug: Crovalimab · For: Atypical Hemolytic Uremic Syndrome
Sites: San Francisco, California; Aurora, Colorado; Atlanta, Georgia · 41 sites in all
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT03157635 · 59 participants · Start Nov 14, 2016 · Primary completion Aug 13, 2026
Drug: Crovalimab; Placebo · For: Paroxysmal Hemoglobinuria, Nocturnal
Sites: Paris, France; Aachen, Germany; Essen, Germany · 15 sites in all
- A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated With Complement InhibitionPivotal-lookingActive, not recruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT04654468 · 51 participants · Start Mar 17, 2021 · Primary completion Feb 10, 2022
Drug: Crovalimab · For: Paroxysmal Nocturnal Hemoglobinuria
Sites: Wuhan, China; Chengdu, China; Guangzhou, China · 5 sites in all
- A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Pediatric Participants With Atypical Hemolytic Uremic Syndrome (aHUS)Pivotal-lookingActive, not recruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT04958265 · 41 participants · Start Nov 17, 2021 · Primary completion Jul 4, 2025
Drug: Crovalimab · For: Atypical Hemolytic Uremic Syndrome
Sites: Aurora, Colorado; Omaha, Nebraska; Hackensack, New Jersey · 20 sites in all
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT04912869 · 30 participants · Start Mar 26, 2022 · Primary completion Dec 23, 2024
Drug: Crovalimab; Placebo · For: Sickle Cell Disease
Sites: Atlanta, Georgia; New York, New York; Salvador, Brazil · 16 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- pyrexia21
- type iii immune complex mediated reaction21
- anaemia20
- off label use15
- haemolysis14
- infection11
- breakthrough haemolysis10
- pneumonia10
- hepatic function abnormal8
- covid-197
- haemoglobin decreased7
- sepsis7
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2024 | 12 |
| 2025 | 54 |
| 2026 | 55 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Phase 3 randomized COMMODORE 1 trial: Crovalimab versus eculizumab in complement inhibitor-experienced patients with paroxysmal nocturnal hemoglobinuria.
Scheinberg P, Clé DV, Kim JS, et al. · Am J Hematol 2024 · Randomized Controlled Trial, Clinical Trial, Phase III
- Phase 3 randomized COMMODORE 2 trial: Crovalimab versus eculizumab in patients with paroxysmal nocturnal hemoglobinuria naive to complement inhibition.
Röth A, He G, Tong H, et al. · Am J Hematol 2024 · Clinical Trial, Phase III, Randomized Controlled Trial
- Safety of Crovalimab Versus Eculizumab in Patients With Paroxysmal Nocturnal Haemoglobinuria (PNH): Pooled Results From the Phase 3 COMMODORE Studies.
Röth A, Fu R, He G, et al. · Eur J Haematol 2025 · Clinical Trial, Phase III, Multicenter Study
- Patient-reported outcomes in patients with paroxysmal nocturnal hemoglobinuria treated with crovalimab and approved C5 inhibitors in the phase III COMMODORE 2 and 1 studies.
Panse J, Han B, Cermak J, et al. · Ann Hematol 2025 · Clinical Trial, Phase III, Randomized Controlled Trial
- Crovalimab treatment in patients with paroxysmal nocturnal haemoglobinuria: Long-term results from the phase I/II COMPOSER trial.
Röth A, Ichikawa S, Ito Y, et al. · Eur J Haematol 2023 · Clinical Trial, Phase II, Clinical Trial, Phase I
- Efficacy and safety of crovalimab versus eculizumab in complement inhibitor-naïve patients with paroxysmal nocturnal hemoglobinuria: Chinese subgroup analysis of the phase 3 COMMODORE 2 study.
Tong H, Lin Z, Yang C, et al. · Ann Hematol 2026 · Randomized Controlled Trial, Clinical Trial, Phase III
Sponsor: Roche (Genentech)
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.